Quarterly ResultMay 4, 2026, 04:19 PM
ADC Therapeutics Q1 Net Loss Narrows to $33.0M; Revenue $20.9M
AI Summary
ADC Therapeutics reported a reduced net loss of $33.0 million for Q1 2026, down from $38.6 million in Q1 2025, with net loss per share improving to $(0.21) from $(0.36). Total revenue decreased to $20.9 million from $23.0 million year-over-year, primarily due to lower license revenues. The company also amended its royalty purchase agreement with HCR, issuing warrants for 9.8 million common shares, and continued to realize benefits from its 2025 restructuring, which focused resources on ZYNLONTA and reduced the workforce by approximately 30%. Operating cash burn significantly decreased.
Key Highlights
- Q1 2026 net loss narrowed to $33.0 million from $38.6 million YoY.
- Q1 2026 total revenue decreased to $20.9 million from $23.0 million YoY.
- Product revenues, net, increased to $20.0 million from $17.4 million YoY.
- Net loss per share improved to $(0.21) from $(0.36) YoY.
- Net cash used in operating activities decreased to $29.7 million from $56.3 million YoY.
- Issued warrants for 9,834,776 common shares to HCR at $3.81 per share.
- Realized benefits from 2025 restructuring, reducing workforce by ~30%.
- Cash and cash equivalents were $231.0 million as of March 31, 2026.
Price Impact
More from ADCT